Protective effects of dimethyl sulfoxide on zymosan-insulted gut barrier impairment

doi:10.12047/j.cjap.5443.2017.049

Abstract

Abstract: Objective: To explore the effect of dimethyl sulfoxide(DMSO) on suppressing the release of gut inflammatory cytokine and re-store of the barrier impairment following zymosan-insulted systemic inflammatory response syndrome (SIRS). Methods: S D rats were randomly divided into four groups:sham with administration of normal saline (SS group); sham with administration of DMSO (DS group); zymosan with administration of normal saline (ZS group); and zymosan with administration of DMSO (ZD group), each group includes two subgroups at 4 h and 24 h after surgery. At 4 h and 24 h after intraperitoneal injection of zymosan (750 mg/kg), the levels of intestinal inflammatory cytokines (tumor necrosis factor-αand interleukin-10) and the activity of diamine oxidase in plasma were examined. Intestinal injury was evaluated by using an intestinal histological score. Results: DMSO suppressed the release of tumor necrosis factor-αand increased interleukin-10 levels in the intestine compared with the ZS group at the corresponding time points. DMSO decreased the level of diamine oxidase in plasma compared with the ZS group. DMSO restored the injury of intestinal villi and the gut injury score was significantly lower than that in the ZS group. Conclusion: DMSO can suppress the release of intestinal inflammatory cytokines and restore zymosan-insulted gut barrier impairment.

Key words: DMSO, zymosan, inflammatory cytokines, gut barrier, rat

ZHANG Hui-ping, MA Li-qian, LV Yi, LUO Hong-min, LI Yu-meng, LIU Rui, HU Sen. Protective effects of dimethyl sulfoxide on zymosan-insulted gut barrier impairment[J]. CJAP, 2017, 33(3): 193-196.

References

[1] Fink MP, Delude RL. Epithelial barrier dysfunction:a unify-ing theme to explain the pathogenesis of multiple organ dys-fu nction at the cellular level[J]. Crit Care Clin, 2005, 21(2):177-196.
[2] Deitch EA, Xu D, Franko L, et al. Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock[J]. Shock, 1994, 1(2):141-145.
[3] Hassoun HT, Kone BC, Mercer DW, et al. Post-injury mul-tiple organ failure:the role of the gut[J]. Shock, 2001, 15(1):1-10.
[4] Santos NC, Figueira-Coelho J, Martins-Silva J, et al. Multi-disciplinary utilization of dimethyl sulfoxide:pharmacologi-cal, cellular, and molecular aspects[J]. Biochem Pharma-col, 2003, 65(7):1035-1041.
[5] Kloesch B, Liszt M, Broell J, et al. Dimethyl sulphoxide and dimethyl sulphone are potent inhibitors of IL-6and IL-8 expression in the human chondrocyte cell line C-28/I2[J]. Lif e Sci, 2011, 89(13-14):473-478.
[6] Sant GR. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis[J]. Urology, 1987, 29(4 Suppl):17-21.
[7] Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis——a practical approach[J]. Urology, 1997, 49(5A Suppl):105-107.
[8] Chiu CJ, McArdle AH, Brown R, et al. Intestinal mucosal lesion in low-flow states. I. A morphological hemodynamic, and metabolic reappraisal[J]. Arch Surg, 1970, 101(4):478-483.
[9] Pillemer L, Ecker EE. Anticomplementary factor in fresh yeast[J]. J Biol Chem, 1941, 137:139-142.
[10] Nauseef WM, Root RK, Newman SL, et al. Inhibition of zymosan activation of human neutrophil oxidative metabolism by a mouse monoclonal antibody[J]. Blood, 1983, 62(3):635-644.
[11] Bonney RJ, Wightman PD, Davies P, et al. Regulation of prostaglandin synthesis and of the selective release of lysoso-mal hydrolases by mouse peritoneal macrophages[J]. Biochem J, 1978, 176(2):433-442.
[12] Goris RJ, Boekholtz WK, van Bebber IP, et al. Multiple-organ failure and sepsis without bacteria. An experimental model[J]. Arch Surg, 1986, 121(8):897-901.
[13] Frasnelli ME, Tarussio D, Chobaz-Peclat V, et al. TLR2 modulates inflammation in zymosan-induced arthritis in mice[J]. Arthritis Res Ther, 2005, 7(2):R370-379.
[14] Chang CK, Llanes S, Schumer W. Inhibitory effect of dimethyl sulfoxide on nuclear factor-kappa B activation and intercellular adhesion molecule 1gene expression in septic rats[J]. J Surg Res, 1999, 82(2):294-299.
[15] Kelly KA, Hill MR, Youkhana K, et al. Dimethyl sulfoxide modulates NF-kappa B and cytokine activation in lipopolysac-charide-treated murine macrophages[J]. Inf ect Immun, 1994, 62(8):3122-3128.
[16] Hollebeeck S, Raas T, Piront N, et al. Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal Caco-2cell model[J]. Toxicol Lett, 2011, 206(3):268-275.
[17] Ahn H, Kim J, Jeung EB, et al. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation[J]. Immunobiology, 2014, 219(4):315-322.
[18] Schottelius AJ, Mayo MW,Sartor RB, et al. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nucle-ar factor kappaB DNA binding[J]. J Biol Chem, 1999, 274(45):31868-31874.
[19] Driessler F, Venstrom K, Sabat R, et al. Molecular mecha-nisms of interleukin-10mediated inhibitor of NF-kappaB ac-tivity:a role for p50[J]. J Clin Exp Immunol, 2004, 135(1):64-73.
[20] Akyurek N, Kafali EM, Muhtaroglu S. The effects of dimethylsulfoxide on experimental hepatic ischemia[J]. Swiss Surg, 2000, 6(1):23-27.
[21] Jo SK, Hu X, Yuen PS, et al. Delayed DMSO administra-tion protects the kidney from mercuric chloride-induced injury[J]. J Am Soc Nephrol, 2004, 15(10):2648-2654.